Trial Profile
Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Carcinoma; Germ cell and embryonal neoplasms; Germ cell cancer; Testicular cancer
- Focus Biomarker; Therapeutic Use
- 01 Feb 2014 Results presented at the 2014 Genitourinary Cancers Symposium.
- 10 Sep 2010 Status changed from recruiting to completed according to ISRCTN.
- 09 Nov 2008 New trial record.